Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Division of Anti-Viral Drugs

Executive Summary

FDA announced Jan. 11 that Center for Drug Evaluation and Research Director Carl Peck will serve as acting director of the division until a permanent director is found. Peck will continue to head CDER. Several weeks ago, Ellen Cooper, who has been the division's director since its establishment in March 1988, requested reassignment to another review section within FDA ("The Pink Sheet" Dec. 24, "In Brief"). Cooper has expressed frustration with the job, citing in particular the pressure from activist groups and FDA's lack of responsiveness.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS018622

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel